Helix BioPharma Corp.: A New Era of Leadership with Dr. Thomas Mehrling
April 10, 2025 – Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ), a clinical-stage oncology company, proudly announces the appointment of Dr. Thomas Mehrling as the new Chief Executive Officer (CEO). The Company’s outgoing CEO, Jacek Antas, will dedicate his focus to his role as Chairman. Dr. Mehrling, who has been instrumental in shaping Helix’s clinical strategy as the Chief Medical Officer (CMO), assumes the helm to deliver on the Company’s ambitious clinical milestones planned for 2025 and beyond.
A Distinguished Career in Oncology
Dr. Mehrling, a renowned Hemato-Oncologist and Pharmacologist, brings over 20 years of experience in pharmaceutical oncology to Helix. He has a proven track record of building successful, global oncology businesses and delivering transformative therapies to the market. Dr. Mehrling’s expertise includes a tenure at Mundipharma International Ltd., where he served various roles, including Head of Business Development, European Director of Oncology, and International Director of Oncology Strategy. During his time at Mundipharma, he introduced groundbreaking cancer drugs across Europe, achieving sales nearing USD 1 billion.
Innovation and Entrepreneurship
In 2013, Dr. Mehrling led the establishment and became the CEO of Mundipharma EDO GmbH, a Swiss-based start-up within the Mundipharma Group dedicated to the development of highly selective inhibitors and targeted medicines for hematological malignancies and solid tumors. In 2019, he founded Laevoroc Medical AG, a privately held, Swiss oncology company. Helix’s acquisition of Laevoroc’s assets laid the foundations for a broader strategic collaboration between Dr. Mehrling and the Company.
A Transformative Impact on the Oncology Industry
Before his tenure at Mundipharma, Dr. Mehrling spent 13 years as an MD at the University Hospital in Frankfurt, where he earned his MD degree from the Department of Internal Medicine (Hemato-oncology and Cardiology) and his PhD in Pharmacology. Dr. Mehrling’s vast experience and expertise will undoubtedly contribute to Helix’s mission to shape a near future where today’s hard-to-treat cancers are viable.
What Does This Mean for You?
As a concerned individual, you may be wondering how this leadership change will impact you. While it is essential to note that this appointment primarily concerns Helix BioPharma Corp., Dr. Mehrling’s extensive background in oncology and his commitment to delivering transformative therapies to the market could potentially lead to advancements in cancer treatment and improved patient outcomes. Stay informed about Helix’s progress and clinical milestones.
A Global Impact
On a larger scale, Dr. Mehrling’s appointment as CEO of Helix BioPharma Corp. signifies a significant step forward in the oncology industry. With a proven track record of introducing groundbreaking cancer drugs and building successful oncology businesses, Dr. Mehrling is poised to lead Helix in shaping a future where today’s hard-to-treat cancers are viable. This could potentially lead to a global impact on cancer treatment and patient care.
Conclusion
In conclusion, Helix BioPharma Corp.’s appointment of Dr. Thomas Mehrling as CEO marks a pivotal moment in the Company’s mission to shape a near future where today’s hard-to-treat cancers are vincible. Dr. Mehrling’s distinguished career in oncology, entrepreneurship, and innovation will undoubtedly contribute to Helix’s ambitious clinical milestones. As an individual, stay informed about Helix’s progress, and as a global community, prepare for potential advancements in cancer treatment and improved patient outcomes. Together, we can shape a future where cancer is no longer a death sentence.
- Helix BioPharma Corp. appoints Dr. Thomas Mehrling as CEO
- Dr. Mehrling has over 20 years of experience in pharmaceutical oncology
- He has a proven track record of building successful oncology businesses
- Dr. Mehrling’s expertise includes introducing groundbreaking cancer drugs to the market
- His appointment could potentially lead to advancements in cancer treatment
- Stay informed about Helix’s progress and clinical milestones
